Abstract:Recent publications have reported that α-synuclein seed amplification assays (SAAs) have potential as biomarker tests for Parkinson disease (PD). This has led to several recommendations: to integrate α-synuclein SAA into care to facilitate an earlier diagnosis of PD 1 -3 ; to incorporate α-synuclein SAA testing into a research-based definition of neuronal α-synucleinopathy, encompassing a pathological process with clinical and preclinical phases 1 -3 ; and to use α-synuclein SAA to guide clinical trial enrollment. Although α-synuclein SAA is a promising tool, caution is needed in deploying α-synuclein SAA in general neurology practice. α-Synuclein SAAs rely on the seeding properties of abnormal α-synuclein in cerebrospinal fluid or other biological samples, including skin biopsies, and measure the kinetics of propagating α-synuclein aggregation. These assays have been developed using postmortem brain tissue, and a 2023 meta-analysis demonstrated that 88% of patients clinically diagnosed with PD have a positive α-synuclein SAA result. 4 However, the usefulness of this assay is influenced by limitations in the published literature and uncertainty in the early diagnosis of PD. The Queen Square Brain Bank (QSBB) clinical diagnostic criteria have been widely used to diagnose PD in clinical research studies and general neurology practice. The QSBB criteria were established by careful clinical documentation of patients who were followed up through their disease course and had pathologically defined PD with Lewy bodies and neurites at autopsy. 5 Although the criteria predated the description of α-synuclein as the major protein in Lewy bodies, they provided a firm clinical basis for α-synuclein–related PD. In sharp contrast, most of the recent articles on α-synuclein SAA have relied on a cross-sectional diagnosis of PD. Carefully conducted longitudinal clinical studies have shown that around 10% of patients diagnosed with PD at their initial neurological assessment have an alternative disorder, including conditions that are more benign (essential tremor, dystonic tremor, or normal aging) and more malignant (Parkinson plus syndromes, progressive supranuclear palsy [PSP], multiple system atrophy [MSA], or corticobasal syndrome). Because a clinical diagnosis of PD can be prone to error when made at a single time point, the QSBB criteria require observing symptoms over time (eg, persistent asymmetry) to make a diagnosis. Similar prospective criteria are included in the Movement Disorder Society's diagnostic criteria for PD, 6 which emphasize the need to observe patients over time to improve diagnostic certainty. The true diagnostic value of α-synuclein SAA cannot be established, therefore, without longitudinal follow-up and, ideally, postmortem examination of patients with both positive and negative α-synuclein SAA results. Many α-synuclein SAA studies have used healthy controls unaffected by neurodegenerative disease. However, the main clinical challenge is not in distinguishing PD from healthy controls but in differentiating PD from MSA, PSP, corticobasal syndrome, normal pressure hydrocephalus, and cerebrovascular disease. The potential cross-reactivity of the α-synuclein SAA across different neurodegenerative disease proteins needs to be established using cerebrospinal fluid samples and postmortem follow-up before α-synuclein SAA can be used in clinical practice. The specificity of α-synuclein SAA is much lower in distinguishing PD from MSA, compared with distinguishing PD from healthy controls. 4 There will also be many patients who have false-positive α-synuclein SAA results because of α-synuclein copathology, such as patients with Lewy body pathology and primary Alzheimer disease. The α-synuclein SAA will enable definition of the effects of copathology in large patient series of other clinically diagnosed neurodegenerative disorders. With respect to asymptomatic individuals, incidental Lewy body pathology occurs in 1 in 6 older adults, who die without any signs of PD. 5 The high rates of α-synuclein SAA positivity reported in patients with clinically diagnosed PSP, Alzheimer disease, Guam amyotrophic lateral sclerosis, and normal pressure hydrocephalus may relate to background copathology. Although reference laboratories have thus far shown a high degree of consistency, there can be variation in reporting from different laboratories. 7 A study examining α-synuclein SAAs in a common set of samples in 3 laboratories showed that assay results were inconsistent for 17% of patients with clinically diagnosed PD at baseline and for 13% of healthy controls at 3 years. There are therefore 3 possible interpretations of a positive α-synuclein SAA finding: (1) true positive with PD, meaning the patient has Lewy body PD and a positive α-synuclein SAA result; (2) true positive with -Abstract Truncated-

In vivo detection of Alzheimer's and Lewy body disease concurrence: Clinical implications and future perspectives

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assay

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer's disease

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease

α‐Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden

Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort

Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra

A crossâ€�sectional study of Î±â€�synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function

α-synuclein as an emerging pathophysiological biomarker of Alzheimer’s disease

Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden

High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases

Association of CSF α-Synuclein Seed Amplification Assay Positivity with Disease Progression and Cognitive Decline: A Longitudinal Alzheimer's Disease Neuroimaging Initiative Study

α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders

α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward

Limitations of α-Synuclein Seed Amplification Assay

Association of CSF α‐synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study

Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers

CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders